Abstract

Hematopoietic stem cell transplant (HSCT) essentially resets the immune system by mobilizing stem cells, ablating the immune system, and reconstituting the immune system with autologous cells. HSCT is being tested as a treatment for multiple sclerosis (MS; NEJM JW Neurol Apr 2015 and JAMA 2015; 313:27). Now, researchers have conducted a phase II trial, enrolling patients from three centers who had poor prognostic features (e.g., expanded disability status scale [EDSS] ≥3.0 within 5 years after disease onset, ongoing disease activity …

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.